We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current SPRY market cap is 1.22B. The company's latest EPS is USD 0.0815 and P/E is 152.02.
| Quarter End | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 500k | 2.07M | 86.58M |
| Operating Income | -10.23M | -13.19M | -15.34M | -21.75M | 47.2M |
| Net Income | -7.17M | -10.29M | -12.52M | -19.13M | 49.93M |
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 1.32M | 30k | 89.15M |
| Operating Income | -32.92M | -89.58M | -35.52M | -67.52M | -3.08M |
| Net Income | -32.95M | -89.48M | -34.68M | -54.37M | 8M |
| Quarter End | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 233.19M | 227.58M | 221.97M | 217.6M | 351.15M |
| Total Liabilities | 2.43M | 3.72M | 6.73M | 16.62M | 94.36M |
| Total Equity | 230.76M | 223.87M | 215.24M | 200.98M | 256.8M |
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 394.8M | 333.47M | 281.44M | 233.19M | 351.15M |
| Total Liabilities | 11.93M | 19.65M | 8.55M | 2.43M | 94.36M |
| Total Equity | 382.88M | 313.82M | 272.89M | 230.76M | 256.8M |
| Quarter End | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -59.27M | -6.71M | -13.99M | -28.46M | 13.55M |
| Investing | -87.18M | -8.51M | -21.16M | -4.34M | -106.1M |
| Financing | 6.9M | 258k | 803k | 1.48M | 72.4M |
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -31.2M | -66.76M | -40.08M | -59.27M | 13.55M |
| Investing | -917k | -66.48M | -199k | -87.18M | -106.1M |
| Financing | 408.51M | 614k | 190.73M | 6.9M | 72.4M |
| Market Cap | 1.22B |
| Price to Earnings Ratio | 152.02 |
| Price to Sales Ratio | 13.64 |
| Price to Cash Ratio | 23.92 |
| Price to Book Ratio | 4.73 |
| Dividend Yield | - |
| Shares Outstanding | 98.12M |
| Average Volume (1 week) | 1.75M |
| Average Volume (1 Month) | 2.05M |
| 52 Week Change | 21.53% |
| 52 Week High | 18.51 |
| 52 Week Low | 7.55 |
| Spread (Intraday) | 0.01 (0.08%) |
| Company Name | ARS Pharmaceuticals Inc |
| Address |
108 w. 13th street wilmington, delaware 19801 |
| Website | https://ars-pharma.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
